STOCK TITAN

Health Catalyst (NASDAQ: HCAT) exec to sell 28,875 restricted shares via MS

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Health Catalyst, Inc. filing notifies a proposed sale of 28,875 restricted common shares to be sold on 02/26/2026. The sale is listed as compensation stock and identifies Morgan Stanley Smith Barney LLC at 1 New York Plaza as the broker.

The filing names Daniel Burton and shows prior restricted stock sales of 55,715 shares on 12/01/2025 for $161,584.64. Shares outstanding are listed as 70,730,884 as of 02/26/2026.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the HCAT Form 144 disclose about planned sales?

The Form 144 discloses a proposed sale of 28,875 restricted common shares on 02/26/2026. The filing lists the sale as compensation stock and names Morgan Stanley Smith Barney LLC as broker.

Who is the reporting person on the HCAT Form 144?

The filing names Daniel Burton in connection with the restricted stock transactions. The document links prior sales by the same person and the planned sale scheduled for 02/26/2026.

What prior transactions are shown in the HCAT excerpt?

The excerpt shows prior restricted stock sales of 55,715 shares on 12/01/2025 with an aggregate value of $161,584.64. These sales are reported in the ‘‘past 3 months’’ section of the form.

Which broker is handling the proposed HCAT sale?

The proposed 28,875 share sale lists Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York, NY, as the broker for transactions scheduled on 02/26/2026.

How many HCAT shares outstanding are shown in the filing?

The excerpt lists 70,730,884 shares outstanding as of 02/26/2026. That figure appears in the securities information section of the filing.